Abstract
Although a large volume of evidence supporting the use of dual antiplatelet therapy in patients with the acute coronary syndrome, there remains major uncertainty regarding the optimal duration of treatment. Clinical trials have varied markedly in the length of treatment. Some systematic reviews and meta-analyses assert that shorter durations of dual antiplatelet therapy are superior because the avoidance of thrombotic events is counterbalanced by the greater risks of significant excess bleeding with definite enhances in all-cause mortality with longer durations. These findings did not demonstrate remarkable heterogeneity according to whether patients had coronary artery disease. Therefore, the potential damages and benefits may differ when applied to the broad patients met in clinical practice who have notably higher complication rates. Clinicians have no definitive information regarding the duration of therapy in patients with the acute coronary disease. The clinical evidence would further clear up future research into strategies for personalized medicine.
Citation
Kivrak T, Erdem K and Karaca I. Dual Antiplatelet Therapy in Acute Coronary Syndrome. SM J Cardiolog and Cardiovasc Disord. 2017; 3(3): 1013.